FREE SHIPPING ON ORDERS OVER $150

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

$29.92

Quantity
- +
Description

doi: 10.3389/fphar.2019.01461

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

Sasaki T et al

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

Paddock et al., 2007)

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

Physiology of obesity and effects on respiratory function

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

A companion study from the Karolinska Institutet in Sweden, published on the same day, reached a broadly similar conclusion, and found that the association weakened once background treatment was taken into account

glp-1 87 kg journey GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 | Summary

You may also like

recommand products